-
Article
Open AccessA randomized phase III study of carfilzomib vs low-dose corticosteroids with optional cyclophosphamide in relapsed and refractory multiple myeloma (FOCUS)
This randomized, phase III, open-label, multicenter study compared carfilzomib monotherapy against low-dose corticosteroids and optional cyclophosphamide in relapsed and refractory multiple myeloma (RRMM). Rel...
-
Article
Therapiekonzepte bei älteren Patienten mit multiplem Myelom
Mit zunehmendem Lebensalter steigt die Variabilität des biologischen Gesamtzustands, weshalb bei älteren Patienten mit multiplem Myelom eine sorgfältige Erhebung von Morbidität, Fragilität und Invalidität empf...
-
Article
Exome sequencing in tracking clonal evolution in multiple myeloma following therapy
-
Article
Erratum: Immunoglobulin heavy/light chain ratios improve paraprotein detection and monitoring, identify residual disease and correlate with survival in multiple myeloma patients
Correction to: Leukemia (2013) 27, 213–219; doi:10.1038/leu.2012.197 Since the publication of this article, the authors have noticed an error within Figure 1, namely that the data for the IgG and IgA patients ...
-
Article
Open AccessImmunoglobulin heavy/light chain ratios improve paraprotein detection and monitoring, identify residual disease and correlate with survival in multiple myeloma patients
The novel heavy/light chain (HLC) assay was used for the detection and measurement of monoclonal immunoglobulins, response evaluation and prognostication. This test allows identification and quantification of ...
-
Article
Continuous treatment with lenalidomide in multiple myeloma: a case report
We present the case of a 72-year-old woman diagnosed with multiple myeloma (MM) in 1992 and treated with lenalidomide plus dexamethasone (LD) as third-line therapy. The patient achieved a complete remission (C...
-
Article
Evaluating the clonal hierarchy in light-chain multiple myeloma: implications against the myeloma stem cell hypothesis
-
Article
Efficacy of the combination of bortezomib and dexamethasone in systemic AL amyloidosis
Bortezomib–dexamethasone (Btz/Dex) is an active regimen in patients with multiple myeloma and has been used in few patients with amyloidosis. Here, we report a retrospective evaluation of the efficacy and toxi...
-
Article
DNA vaccines to target the cancer testis antigen PASD1 in human multiple myeloma
We previously described PASD1 as a new cancer testis antigen in multiple myeloma (MM) that is retained post-therapy, suggesting the use of vaccination strategies to induce anti-PASD1 immunity in a setting of m...
-
Article
Chronic lymphocytic leukaemia – emerging treatment options: a report from the ASH Meeting 2009
Chronic lymphocytic leukaemia (CLL) in early stages does not require immediate treatment. Although some patients progress rapidly, institution of treatment in an asymptomatic phase has so far not been demonstr...
-
Article
Konventionelle Behandlung von Patienten mit multiplem Myelom
Für ältere Patienten sowie für jene jüngeren Patienten mit multiplem Myelom, für die eine autologe Transplantation nicht in Frage kommt, stellt die konventionelle Behandlung die Therapie der Wahl dar. In den l...
-
Article
Expression of MUM1/IRF4 mRNA as a prognostic marker in patients with multiple myeloma
-
Article
IgM-expressing Waldenstrom's macroglobulinemia tumor cells reveal a potential for isotype switch events in vivo
-
Article
Bortezomib in relapsed multiple myeloma: response rates and duration of response are independent of a chromosome 13q-deletion
Studies of bortezomib in patients with relapsed multiple myeloma (MM) suggested that bortezomib may be active even in the presence of adverse prognostic factors. We therefore evaluated 62 patients with relapse...
-
Article
Konventionelle Therapie des multiplen Myeloms
Melphalan/Prednisolon, hoch-dosiertes Dexamethason und Polychemotherapie gehören zu den etablierten „konventionellen“ Therapien bei Patienten, die für eine Hochdosistherapie mit Stammzelltransplantation nicht ...
-
Article
Supportive Therapie
Durch Hochdosistherapie und neue Therapieverfahren konnte die Überlebenszeit von Patienten mit multiplem Myelom in den letzten Jahren deutlich verbessert werden. Besonders in Phasen der Krankheitsprogression m...
-
Article
Absence of clonal chromosomal relationship between concomitant B-CLL and multiple myeloma – a report on two cases
B-cell chronic lymphocytic leukemia (B-CLL) and multiple myeloma (MM) are chronic B-cell malignancies that represent different stages of B-cell maturation. Occasionally, both diseases are present in the same ...
-
Article
Deletions of chromosome 13q in monoclonal gammopathy of undetermined significance
Since deletion of chromosome 13q is a clinically relevant feature in multiple myeloma (MM), we analyzed bone marrow plasma cells from 29 patients with monoclonal gammopathy of undetermined significance (MGUS) ...
-
Article
Klinik, Diagnose und Prognose des Multiplen Myeloms
-
Article
A case of bone marrow mastocytosis associated with multiple myeloma
Mastocytosis is a term used for a spectrum of disorders characterized by abnormal growth and accumulation of mast cells. The cutaneous variants of the disease have to be distinguished from systemic mastocytos...
